EnsiliTech is improving the shelf-life and global accessibility of vaccines and other biological therapeutics by combatting cold chain transport and storage issues. Its novel ensilication technology, designed for both existing and new biopharmaceutical formulations, encases thermally unstable biomolecules within silica nanoshells to prevent environmental degradation. This eliminates the need for cold chain requirements that are expensive, prone to failure and generate significant carbon dioxide emissions.

Glaia is developing innovative solutions to optimise agricultural plant performance to help food security and fight climate change. Using disruptive technology, its sustainable agrochemicals unlock the potential of the photosynthetic process, enabling plant cells to more efficiently convert energy to biomass to increase crop yields without increasing inputs. This results in greater profits for growers and reduced greenhouse emissions, delivering more sustainable global food production.

Argonaute RNA is developing safe, reliable and targeted methods of temporarily silencing genes in different tissue cells. It does this via the proprietary modification of small interfering RNA (siRNA), using a novel stabilisation method to overcome previous obstacles to developing siRNA drugs for healthcare.

Zentraxa is precision engineering biomaterials, pushing the boundaries of biopolymer synthesis to develop sustainable, performance-enhancing ingredients for everyday products. Its proprietary technological platform (Zentide) overcomes the biodesign limits of existing, conventional peptide synthesis by designing, producing and testing complex, novel peptides with one universal process. Zentraxa creates bespoke solutions for a range of industries by combining key features from different naturally-occurring proteins, such as stiffness, adhesion or thermal stability.

Argonaute RNA is developing safe, reliable and targeted methods of temporarily silencing genes in different tissue cells. It does this via the proprietary modification of small interfering RNA (siRNA), using a novel stabilisation method to overcome previous obstacles to developing siRNA drugs for healthcare.

Dimension Biotechnologies is addressing unmet global vascular health challenges by improving diagnostic tools. Its transformative technology non-invasively monitors microscopic blood vessels at the biochemical level enabling doctors, drug developers and scientists to rapidly assess microvascular health and disease.